Verition Fund Management
ARCT icon

Verition Fund Management’s Arcturus Therapeutics ARCT Stock Holding History

Verition Fund Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-63,184
Closed -$822K – 3742
2025
Q2 		$822K Buy
+63,184
New +$747K ﹤0.01% 2610
2025
Q1 		– Sell
-10,599
Closed -$180K – 3312
2024
Q4 		$180K Sell
10,599
-7,514
-41% -$141K ﹤0.01% 3002
2024
Q3 		$420K Buy
+18,113
New +$387K ﹤0.01% 2426
2015
Q2 		– Sell
-7,900
Closed -$311K – 607
2015
Q1 		$311K Sell
7,900
-7,914
-50% -$348K 0.04% 192
2014
Q4 		$413K Hold
15,814
– – 0.09% 104
2014
Q3 		$1.71M Hold
15,814
– – 0.24% 58
2014
Q2 		$1.92M Sell
15,814
-28,513
-64% -$3.44M 0.2% 66
2014
Q1 		$5.63M Buy
+44,327
New +$6.57M 0.86% 17

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Verition Fund Management's ARCT Position: Q3 2025 in Review

Verition Fund Management sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 63,184 shares — an estimated $822K sold.

Verition Fund Management first reported a position in ARCT in Q1 2014 and held it in 8 quarters. The position peaked at $5.63M in Q1 2014. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Verition Fund Management reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 63,184 Arcturus Therapeutics shares in Q3 2025, an estimated $822K.
  • Verition Fund Management first reported a position in Arcturus Therapeutics in Q1 2014 and held it in 8 quarters.
  • Verition Fund Management's Arcturus Therapeutics position peaked at $5.63M in Q1 2014.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.